A Phase 1 interventional study of Vortioxetine (Lu AA21004) and Placebo in Depression, sponsored by H. Lundbeck A/S. Completed at 1 site in United Kingdom. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-09-25.
Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing vortioxetine in Depression — 3 open to participants now, 3 under way, none of them phase 3. Vortioxetine · Depression.
Among the 30 studies testing vortioxetine in Depression, this one is the 18th largest by enrollment, is one of 2 that started in 2012, is one of 2 in phase 1, and was the 14th registered.
8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.
Browse Depression studies →3 of the 30 studies testing vortioxetine in Depression are open now, in 2 countries. Recruiting first, the newest first:
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 13–18
IRCCS San Raffaele Roma · Sites in Italy
Ages 30–80
Marianna Amboni
Ages 18+
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.
This study: 25 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 16 · Phase 4 11
First in 2008; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 81 across 7,078 interventional studies indexed under Depression.
Median enrollment 223 across the 30 interventional studies. Of the 22 that completed or were terminated, 17 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 30 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
11 studies in Depression by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 11 finished, 4 (36%) have results posted.
Among the 11 studies in Depression by H. Lundbeck A/S, this one is the 8th largest by enrollment, is one of 2 that started in 2012, is the only one in phase 1, and was the 9th registered.
H. Lundbeck A/S’s Depression studies by the year they started, since 2007.
2 of the studies testing vortioxetine in Depression that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06805266Marianna AmboniVortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease | 2026-12 |
| NCT05814640First Affiliated Hospital of Chongqing Medical UniversitySequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies testing vortioxetine in Depression, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 11 in Depression:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if Vortioxetine 20 mg/day will lead to changes in neural activity (BOLD signal), as measured using fMRI, in brain areas associated with executive functioning and memory during cognitive task performances compared to placebo in subjects remitted from depression and in controls, and to explore if Vortioxetine will lead to improved cognitive performance in the absence of depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All subjects must have:
Subjects remitted from depression must:
Control group subjects must:
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Drug: Vortioxetine (Lu AA21004)
Drug: Placebo
encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
Also known as: Brintellix
capsules, orally, once daily for 13 to 14 days
Effect of Vortioxetine on BOLD signal in fMRI of the brain areas associated with executive function (working memory)
Time frame: Day 1 to Day 13
Effect of Vortioxetine on BOLD signal in fMRI of the brain areas associated with spatial memory
Time frame: Day 1 to Day 13
Effect of Vortioxetine on cognitive performance (executive function, memory, speed of processing, attention, cognitive flexibility) and emotional processing
Time frame: Day 1 to Day 13
The record gives a start of Jul 2012 and a primary completion of Sep 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine